BioNote Inc.
BioNote, Inc., manufactures and sells in-vitro diagnostic animal medicines in South Korea. It offers animal diagnostics products, such as fluorescence immunoassay, molecular diagnostics, clinical biochemistry, rapid immunoassay, and enzyme-linked immunosorbent assay products. The company also provides bio-content products, including rapid immunoassay for humans, human intermediate goods, and bio-… Read more
BioNote Inc. (377740) - Total Liabilities
Latest total liabilities as of March 2023: ₩188.76 Billion KRW
Based on the latest financial reports, BioNote Inc. (377740) has total liabilities worth ₩188.76 Billion KRW as of March 2023.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
BioNote Inc. - Total Liabilities Trend (2019–2022)
This chart illustrates how BioNote Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
BioNote Inc. Competitors by Total Liabilities
The table below lists competitors of BioNote Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Xi S And D Inc
KO:317400
|
Korea | ₩526.18 Billion |
|
Compañía Industrial El Volcán S.A
SN:VOLCAN
|
Chile | CL$122.25 Billion |
|
Able Global Bhd
KLSE:7167
|
Malaysia | RM259.17 Million |
|
Thumzup Media Corporation Common Stock
OTCQB:TZUP
|
USA | $882.70K |
|
Positivo Tecnologia S.A
SA:POSI3
|
Brazil | R$2.84 Billion |
|
InsCorp Inc
OTCQX:IBTN
|
USA | $973.45 Million |
Liability Composition Analysis (2019–2022)
This chart breaks down BioNote Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 9.24 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BioNote Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BioNote Inc. (2019–2022)
The table below shows the annual total liabilities of BioNote Inc. from 2019 to 2022.
| Year | Total Liabilities | Change |
|---|---|---|
| 2022-12-31 | ₩156.85 Billion | -27.70% |
| 2021-12-31 | ₩216.93 Billion | +1.02% |
| 2020-12-31 | ₩214.74 Billion | +960.23% |
| 2019-12-31 | ₩20.25 Billion | -- |